Evidence map›Paper›PMID 38283903›Full record

ReviewF1000Research2023

Emerging pneumococcal serotypes in Iraq: scope for improved vaccine development.

Haider N Dawood, Ali H Al-Jumaili, Ahmed H Radhi, Delan Ikram, Ali Al-Jabban

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in F1000Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Vancomycin ResistanceSage open pediatrics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Haider N DawoodAl Immamin al kadhimin Medical City, Baghdad, 10011, Iraq.
Ali H Al-JumailiMerit consultant pediatrician, Baghdad, 10011, Iraq.ORCID 0000-0002-5731-4890
Ahmed H RadhiF.i.c.m.s/ C.M, Center for disease control and prevention, Baghdad, Iraq.ORCID 0000-0003-2703-1539
Delan IkramPfizer, Baghdad, Iraq.ORCID 0009-0000-3794-1371
Ali Al-JabbanPfizer, Baghdad, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pneumococcal disease is a global public health concern as it affects the young, aged and the immunocompromised. The development of pneumococcal vaccines and their incorporation in the immunization programs has helped to reduce the global burden of disease. However, serotype replacement and the emergence of non-vaccine serotypes as well as the persistence of a few vaccine serotypes underscores the need for development of new and effective vaccines against such pneumococcal serotypes. In the Middle East, places of religious mass gatherings are a hotspot for disease transmission in addition to the global risk factors. Therefore, the periodic surveillance of pneumococcal serotypes circulating in the region to determine the effectiveness of existing prevention strategies and develop improved vaccines is warranted. Currently, there is a lack of serotype prevalence data for Iraq due to inadequate surveillance in the region. Thus, this review aims to determine the pneumococcal serotypes circulating in Iraq which may help in the development and introduction of improved pneumococcal vaccines in the country.

Indexed as

Pneumococcal InfectionsStreptococcus pneumoniaeAgedHumansIraqPneumococcal VaccinesSerogroupPneumococcal VaccinesIraqPneumococcal diseasePneumococcal serotypesPneumococcal vaccinesSerotype replacement

Identifiers

PMID38283903
PMCPMC10811421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.